Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments

Ann Acad Med Singap. 2022 Dec;51(12):752-754. doi: 10.47102/annals-acadmedsg.2022430.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / therapeutic use
  • Humans
  • Hydroxylamines
  • Pharmacogenetics*
  • Ritonavir* / therapeutic use

Substances

  • molnupiravir
  • nirmatrelvir
  • Ritonavir
  • Hydroxylamines
  • Antiviral Agents